Status:
COMPLETED
DMT310-009 Topical in the Treatment of Acne Vulgaris
Lead Sponsor:
Dermata Therapeutics
Conditions:
Acne Vulgaris
Eligibility:
All Genders
9+ years
Phase:
PHASE3
Brief Summary
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris
Eligibility Criteria
Inclusion
- Patient sex at birth, male or non-pregnant female at least 9 years of age
- Clinical diagnosis of moderate to severe acne vulgaris as determined by:
- Investigator's Global Assessment (IGA) at Randomization; Patient has at least 20 inflammatory lesions and at least 20 noninflammatory lesions on the face
- Patient is willing to apply the Investigational Product as directed
- Patient is willing and able to comply with the protocol
Exclusion
- Patient is pregnant or planning to become pregnant
- Patient is taking a topical therapy on the face which may affect the patient's acne
Key Trial Info
Start Date :
December 8 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2025
Estimated Enrollment :
520 Patients enrolled
Trial Details
Trial ID
NCT06090721
Start Date
December 8 2023
End Date
April 30 2025
Last Update
August 22 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Dermatology Clinical Research, Inc.
Freemont, California, United States, 94538
2
DermResearch
Austin, Texas, United States, 78759